Kornimate/medical-research-clean huggingface dataset:
nutrition under noninvasive ventilation

Conditions: Noninvasive Ventilation; Nutrition Therapy; Respiratory Insufficiency

Summary: even though nutrition is a fundamental component of intensive care unit (icu) therapy, critically ill patients are frequently malnourished, a factor well known for its strong association with a higher risk of complications, prolonged icu/hospital length of stay, and greater icu readmission and mortality rates. noninvasive ventilation (niv) use has increased considerably over the past twenty years, making this supportive technique a keystone of acute respiratory failure (arf) treatment. in this setting, respiratory support is provided through an interface, usually a mask or a helmet, that frequently represents an important obstacle to nutrition delivery, making oral intake impossible and posing the necessity to start enteral (en) or parenteral nutrition (pn). moreover, while critical care guidelines regarding nutritional management of patients receiving mechanical ventilation (mv) are well established, data and recommendations about the appropriate nutritional support to patients in niv are still very limited. due to this limited data, we want to describe characteristics and nutritional management of patients undergoing niv in icu, and to evaluate the difference between the mean caloric and protein intake of these patients and the recommended caloric and protein target for critically ill patients. secondarily, we want to evaluate the difference of the caloric and protein intake among groups of patients undergoing different nutritional modality and to assess potential associations of the nutritional characteristics with patient outcomes.


Eligibility criteria:
inclusion criteria: * adult patients; * admission to the intensive care unit of maggiore della carità university hospital from march 1st 2020 to february 28th 2023; * noninvasive ventilation treatment for acute respiratory failure of any cause; * duration of noninvasive ventilation treatment of more than two days; * informed consent signed. exclusion criteria: * patients under 18 years of age; * duration of noninvasive ventilation treatment of less than two days.
study of in-line pressure using various techniques of subcutaneous administration of fluids enabled by human recombinant hyaluronidase (infuse-at1a)

Conditions: Dehydration

Summary: the purpose is to characterize the in-line pressure profiles associated with several infusion technique factors during subcutaneous (sc) infusion of lactated ringer's solution, preceded by recombinant human hyaluronidase (hylenex). the safety and tolerability of hylenex-augmented sc infusion of lactated ringer's solution fluid is also being evaluated.


Eligibility criteria:
inclusion criteria: * male or female, aged 18 to 60 years, inclusive. * body mass index 19.0 to 35.0 kg/m2 * intact normal skin without potentially obscuring tattoos, pigmentation, or lesions on the upper back in the area intended for infusion * free from any clinically significant abnormality on the basis of medical/medication history or physical examination * vital signs and clinical laboratory parameters within normal range or, if outside normal range, deemed not clinically significant * negative urine drug and alcohol screens. exclusion criteria: * upper back pathology that could interfere with study outcome. * history of congestive heart failure, known coronary heart disease, active or recent pulmonary disease, or renal insufficiency. * rales on lung auscultation. * known allergy to hyaluronidase or any other ingredient in the formulation of hylenex recombinant * treatment with furosemide, benzodiazepines, or phenytoin. * pregnancy or breastfeeding. * exposure to any experimental drug within 30 days prior to study admission, or previous participation in this study. * any other reason which, in the investigator's opinion, would prevent the safe participation in the study.

Keywords: dehydration fluid therapy hyaluronoglucosaminidase hyaluronidase hypodermoclysis clysis subcutaneous hydration subcutaneous rehydration hyaluronan rhuph20
comparison of different oxygen delivery strategies during resuscitation of babies

Conditions: Prematurity; Oxidative Injury; Respiratory Distress

Summary: preterm infants are born with immature lungs and often require help with breathing shortly after birth. this currently involves administering 100% oxygen. unfortunately, delivery of high oxygen concentrations leads to the production of free radicals that can injure many organ systems. term and near-term newborns deprived of oxygen during or prior to birth respond as well or better to resuscitation with room air (21% oxygen) compared to 100% oxygen. however, a static concentration of 21% oxygen may be inappropriate for preterm infants with lung disease. our study will investigate how adjusting the amount of oxygen given to sick preterm newborns will affect the ability to maintain a safe oxygen level in their blood. each infant will be assigned to receive one of three treatments at birth. resuscitation will either start with 21% oxygen and be increased if needed, 100% oxygen and be decreased if needed or 100% oxygen with no changes made (current standard of treatment). the first two groups will have adjustments in oxygen concentration as needed to reach a safe target range of blood oxygen saturation. we anticipate that preterm newborn infants resuscitated with higher oxygen concentrations will have higher than "normal" levels of oxygen in their blood while those resuscitated initially with lower concentrations of oxygen will be more likely to have "normal" oxygen levels in their blood. all premature infants will have a surface probe placed on the right hand to measure the saturation of blood with oxygen. following the resuscitation, treatment will proceed as per standard of care until hospital discharge. all infants will be admitted to the neonatal intensive care unit given their prematurity. the purpose of this study is to investigate how safely restricting the amount of oxygen delivered to newborns during resuscitation will affect the amount of oxygen in their blood. hypothesis: in this randomized control trial, infants resuscitated with a "low oxygen delivery (lod)" strategy (initiation of resuscitation with 21% o2) will remain normoxemic for the greatest proportion of time during resuscitation and infants resuscitated with a "high oxygen delivery (hod)" strategy (100% o2 used for the entire resuscitation) will be normoxemic for the smallest proportion of time during resuscitation.


Eligibility criteria:
inclusion criteria: * inborn * \<= 32 weeks gestation * respiratory support needed during resuscitation. respiratory support is defined as provision of continuous positive airway pressure or positive pressure ventilation delivered via either a face mask or an endotracheal tube. exclusion criteria: * lethal anomalies * cyanotic congenital heart disease * known hemoglobinopathy * risk of persistent pulmonary hypertension
covid-19 in lupus patients

Conditions: Systemic Lupus Erythematosus; Covid-19

Summary: the covid-19 pandemic is a major public health issue. potential treatments are essential to control the infection. hydroxychlorquine is currently tested in several clinical trials to evaluate its efficiency.the objective of this study was to evaluate the symptoms related to covid-19 occuring in patients with systemic lupus erythematosus (sle)

introduction:the covid-19 pandemic has had a major impact on many countries on the sanitary and economic level. finding an efficient cure is paramount in order to reduce its severity and mortality. several medications are currently under investigation. among them, hydroxychloroquine can prevent viral replication at several sites and has been shown efficient in vitro. several clinical trials are in progress to evaluate its efficiency in vivo. however, no study so far has evaluated the covid-19 infection in patients with sle. objectives and methods: the primary objective was to describe the prevalence and the severity of covid-19 infection in patients wih systemic lupus erythematosus. the secondary objective was to compare these parameters in patients treated by hydroxychloroquine and those not treated by hydroxychloroquine. this observational study of a historical-prospective cohort focuses on all adult lupus patients seen during the last year in the departments of rheumatology and nephrology in chu montpellier. it will collect information concerning the patient's condition, treatments and main comorbidities (cardio-vascular, respiratory, hepatic and immune depression), as well as symptoms suggesting covid-19 infection, its confirmation and its course and severity.

Eligibility criteria:
inclusion criteria: - adult patient with systemic lupus erythematosus seen during the last year in the departments of rheumatology or nephrology exclusion criteria: - patient not speaking french nor english

Keywords: systemic lupus erythematosus hydroxychloroquine
hop compounds on the immune system in overweight people

Conditions: Inflammatory Response

Summary: the aim of the present study is to determine the effect of iso-alpha acids and xanthohumol from hops on the immune response in overweight participants.

the aim of the present study is to investigate whether the oral intake of xanthohumol and iso-alpha acids has different protective effects on the immune response of isolated blood cells from overweight people with people with incipient metabolic diseases, what the time course of the effect is and whether the levels of the substances differ from normal-weight individuals. after taking a fasting blood sample, the study participants receive one of the study drinks and a light breakfast. both should be consumed within 15 minutes. further blood samples are taken 1, 2, 3, 4 and 6 hours after the drinks have been consumed. to assess the effect of xanthohumol and iso-alpha acids or a combination of both, clinical parameters, blood lipids, blood glucose, uric acid and inflammatory markers will be determined. furthermore, blood cells, isolated from blood samples of each time point, will be stimulated for measuring inflammatory markers.

Eligibility criteria:
inclusion criteria: * bmi 25 - 29,9 kg/m² as well as one or more of the following incipient metabolic diseases: * pre-diabetes (fasting blood glucose 100-125 mg/dl), * fatty liver (grade 1-3), * high-normal blood pressure to mild hypertension (grade 1, systolic 140-159 mmhg) exclusion criteria: * history of diseases that could falsify the study results * inflammatory bowel diseases * malignant diseases of the gastrointestinal tract * food allergies * malabsorption * kidney or liver disease (except simple fatty liver) * symptomatic heart failure * taking medication to treat these diseases * consumption of special diets (e.g. vegan, gluten-free) * pregnancy
vivio as (aortic stenosis) algorithm optimization study

Conditions: Aortic Stenosis

Summary: optimize a candidate software algorithm using data collected with the vivio system for use as an aid in the identification of heart sounds associated with severe aortic stenosis

prospective, non-randomized, single-center study of adult subjects referred for echocardiography. total of 200 enrolled subjects at 1 site enrolled subjects will undergo: vivio system data capture, standard of care transthoracic echocardiogram (tte). vivio analysis will not be available to non-avicena personnel

Eligibility criteria:
inclusion criteria: 1. adult subjects (21 years of age or older). 2. referred for transthoracic echocardiography by physician/primary care provider/cardiologist. 3. willing and able to participate in all study evaluations and allow access to medical testing and records. 4. ability to understand and sign an informed consent or have a legally authorized representative to provide informed consent on behalf of the subject. exclusion criteria: 1. acute coronary syndrome, cardiogenic shock or the need for inotropic/mechanical circulatory support. 2. need for bedside echocardiogram (inpatient). 3. prosthetic device previously implanted at aortic valve position. 4. inability to palpate carotid pulse 5. history of carotid sinus hypersensitivity (i.e. fainting in response to touching or positioning the neck). 6. history of significant carotid artery disease or treatment (surgery, stenting, \> 50% stenosis in both left and right carotid artery). 7. open skin lesions at target site of vivio examination.
effect of licorice and hydrochlorothiazide on plasma potassium

Conditions: Hypokalemia

Summary: this clinical trial is designed to study the effect of the combination of licorice and hydrochlorothiazide on plasma potassium levels in volunteers. in one arm, 10 healthy volunteers will be given 32 grams of licorice a day together with a 25 mg dose of daily hydrochlorothiazide for 14 days. this combination is compared with 32 grams of licorice a day for 14 days given in the other arm. the study is a randomized, open-label cross-over trial. there is at least a 3-week wash-out between the arms. the hypothesis is that the combination of licorice and hydrochlorothiazide will cause hypokalemia. the main outcome measure is the change in the plasma level of potassium between the arms.


Eligibility criteria:
inclusion criteria: * healthy volunteer * age 18-40 years exclusion criteria: * any continuous medication * any significant disease * hypotension or hypertension * allergy to licorice or hydrochlorothiazide * pregnancy and breast feeding * fear of needles and previous difficult blood samplings * substance abuse * participation in another clinical drug trial within 1 month of enrollment
chidamide, venetoclax, and azacitidine for newly diagnosed acute myeloid leukemia

Conditions: AML; Acute Myeloid Leukemia

Summary: to evaluate the feasibility, effectiveness and safety of chidamide combined with venetoclax and azacitidine in the treatment of newly diagnosed acute myeloid leukemia (aml) who are not suitable for intensive chemotherapy.


Eligibility criteria:
inclusion criteria: * （1）age ≥18 years old, no gender limit ; * （2）be diagnosed with aml (non-m3) according to who 2016 standards; * （3）no previous treatment; * （4）ineligible for intensive chemotherapy based on the following definitions: ≥75 years of age or 18 to 74 years of age with at least one of the following comorbidities: eastern cooperative oncology group (ecog) performance status of 2 or 3 a history of cardiac disease such as congestive heart failure treatment is required, or ejection fraction ≤ 50%, or chronic stable angina, diffusing capacity of lung for carbon monoxide (dlco) ≤ 65%, or forced expiratory volume in first second (fev1) ≤ 65%, creatinine clearance ≥ 30 ml/min to \ 1.5 to ≤ 3.0 × uln, other comorbidities that are not suitable for intensive chemotherapy in the physician's judgment. * （5）subjects must have an ecog performance status score of: 0 to 2 for subjects aged ≥ 75 years or 0 to 3 for subjects aged ≥ 18 to 74 years. * （6）other comorbidities that are not suitable for intensive chemotherapy in the doctor's judgment; * （7）expected survival time ≥3 months; * （8）have the ability to understand and be willing to sign the informed consent form for this study. exclusion criteria: * (1) combined with other malignant tumors * (2) have ever received treatment with chidamide and / or venetoclax or azacitidine; * (3) the risk is assessed as low risk according to the nccn 2022 guidelines \[t(8;21)(q22;q22.1);runx1-runx1t1, inv(16)(p13.1q22) or t(16;16 )(p13.1;q22);cbfb-myh11 \] ; * (4) the subject is known to have aml central nervous system (cns) infiltration; * (5) have undergone cardiac angioplasty or stent placement within 12 months before signing the informed consent form , or have a history of myocardial infarction, unstable angina, or other clinically significant heart disease; * (6 ) active infections (including bacterial, fungal or viral infections) and organ bleeding that cannot be controlled clinically; * (7) pregnant or lactating women; * (8) participated in any other clinical research within 3 months before signing the informed consent form ; * (9 ) the researcher believes that it is not suitable to participate in this study;
effect of aerobic training on oxidative stress markers in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: parkinson's disease is a chronic, neurodegenerative disorder characterized with the loss of dopamine-producing neurons. this loss is likely to be related with several environmental and genetic factors. one of the most important factor that is responsible for the initation and progression of the disease is oxidative stress. exercise training, especially aerobic training, can change the levels of oxidative markers because exercise can lead to decrease oxidative stress in patients with parkinson's disease. therefore, this study aims to investigate (1) the effect of aerobic training on total antioxidant status, total oxidant status, glutathione, oxidative glutathione, and zonulin levels, (2) the relationship between the change of motor symptoms and disease severity and the change of total antioxidant status, total oxidant status, glutathione, oxidative glutathione, and zonulin levels.


Eligibility criteria:
inclusion criteria: * at least 40years of age * diagnosed with parkinson's disease * hoehn and yahr stage of 1 and 3 exclusion criteria: * any other neurologic disorders, * any cardiovascular, orthopedic, vestibular or rheumatic conditions that impact exercise training * visual, auditory, and perception problems.

Keywords: parkinson disease exercise total antioxidant status total oxidant status glutathione oxidative glutathione zonulin
integrated diagnostics for early diagnosis of liver disease

Conditions: Non-Alcoholic Fatty Liver Disease; Non-alcoholic Steatohepatitis; Alcoholic Liver Disease; Liver Fibroses

Summary: this is an observational study that will explore the hypothesis that by combining data from patients with liver disease with novel blood biomarkers, single nucleotide polymorphism (snp) analysis and faecal microbiome analysis. the investigators will improve diagnosis of liver fibrosis compared to the current available diagnostic tools.

liver disease is a silent epidemic. four in ten people in the north west are likely to have evidence of liver disease. a small but significant proportion of these patients develop scarring, leading to end-stage cirrhosis. all too frequently this is detected in very advanced stages, where treatment cannot reverse the condition. it is one of the uk's largest health challenges. at present clinicians use a wide range of single tests that individually struggle to identify disease and high-risk patients early. the investigators are implementing a new pathway for the assessment of patients with abnormal liver blood tests or high risk for liver disease. this novel pathway will allow assessment of patients in community liver assessment clinics (clac) with the expectation that only 20% of patients assessed would need to be seen in secondary care for further assessment. the investigators expect, to be assessing, 750 patients per year in this pathway. this pathway will bring together a large group of patients with liver disease. as part of the clinical assessment the investigators will be undertaking investigations to diagnose disease and assess extent. this will generate significant information, that the investigators currently use in isolation to make the aforementioned assessments. in this study, the investigators would like to bring together all this data into a curated database. to this end, the investigators would offer all patients who attend the clac for clinical need to enrol into the study. this would generate a database to combine all data, alongside some other, non-invasive tests, done alongside routine clinical tests. this project will address this lack of answers by teaming up with innovative companies to make software that joins together a wide range of different tests to make an algorithm to detect disease earlier.

Eligibility criteria:
inclusion criteria: * all patients referred to community liver assessment clinic. * male or female \> 18 years of age. * females will be non-pregnant and non-lactating. exclusion criteria: * age \< 18 years. * pregnancy/breast-feeding. women of childbearing potential (not \>2 years post- menopausal and/or not surgically sterilised) must have a negative blood serum pregnancy test. * isolated bilirubinaemia. * known pre-existing liver disease. * acutely unwell. * suspected malignancy.
pilairo lab market research

Conditions: Obstructive Sleep Apnea

Summary: the purpose of the study is to observe the pilairo mask in a lab setting.

the purpose of the study is to observe the pilairo mask in a lab setting, compared to other commercially available masks for continuous positive airwary pressure (cpap) therapy.

Eligibility criteria:
inclusion criteria: * apnea hypopnea indea \>15 from diagnostic study * minimum 18 years of age exclusion criteria: * inability ot give informed consent * history of intolerance to cpap * anatomical or physiological conditions making cpap therapy inappropriate
efficacy and safety of bufy01 versus svs20 in the treatment of dry eye disease

Conditions: Dry Eye Disease

Summary: the goal of this interventional investigation is to compare bufy01 with svs20 in the treatment of patients with dry eye disease. the main questions it aims to answer are: * is bufy01 non-inferior to svs20 in terms of signs of ded? * is bufy01 non-inferior to svs20 in terms of symptoms of ded? participants will be asked to: * visit the trial site at 4 different timepoints * use the allocated study treatment everyday until the end of the study (during 3 months) * be examined by the investigator * complete several questionnaires * return unused study treatment. researchers will compare bufy01 to svs20 to see if both study treatments provide similar effects on signs and symptoms of the disease, together with comparable safety.


Eligibility criteria:
inclusion criteria includes: * at least a 3-month documented history of bilateral dry eye syndrome needing artificial tears; * at least one eye with oxford score ≥ 4 and ≤ 9; * at least one objective sign of tear deficiency (in at least one eligible eye); * having a health insurance. exclusion criteria includes: * wear of contact lenses starting within the last 2 months; * best-corrected visual acuity (bcva) \< 1/10; * severe ded with one of the listed conditions: * severe blepharitis; * seasonal allergy; * any issues of the ocular surface not related to ded; * history of ocular trauma, infection or inflammation not related to ded; * history of ocular surgery, including laser surgery; * unstable glaucoma; * use of artificial tears with preservative within the last 2 weeks; * systemic (enteral or parenteral) or local (topical) use of one of the listed medications: * known hypersensitivity to any constituent of the study treatments; * pregnancy or breastfeeding; * participation in another clinical study within the last 90 days; * legally restricted autonomy, freedom of decision and action.